Chemours' (CC) Buy Rating Reaffirmed at Barclays

Remigio Civitarese
Dicembre 8, 2017

Of the analysts who provided ratings, 1 rated the company a Hold, and 5 rated it a Strong Buy.

According to Zacks, "Chemours Company is involved in chemical business". The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. Chemours Company is headquartered in Wilmington.

Several other research analysts have also commented on the company. Goldman Sachs Group lowered Chemours from a buy rating to a neutral rating and set a $55.00 price objective on the stock.in a research report on Wednesday. Chemours is available at price-to-earnings ratio of 33.12x, showing us it is overvalued compared to the U.S. market average ratio of 19.5x, and overvalued based on current earnings compared to the chemicals industry average of 21.28x. BidaskClub downgraded shares of Chemours from a "buy" rating to a "hold" rating in a research note on Friday, August 11th. The stock has "Hold" rating by Argus Research on Friday, September 18. At the moment, the average analyst rating for CC is Moderate Buy. The company's stock had a trading volume of 5,419,457 shares, compared to its average volume of 2,773,013. Chemours Co has a 12 month low of $5.82 and a 12 month high of $46.02. The firm has a market capitalization of $7.59 billion, a P/E ratio of 71.96 and a beta of 3.50.

Chemours (NYSE:CC) last announced its earnings results on Monday, May 1st.

Wall Street analysts, on average, are forecasting the company's EPS to be 0.97, compared to 0.35 reported in the same quarter past year. Chemours had a return on equity of 81.19% and a net margin of 2.78%. The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.59 billion. This illustrates a relatively optimistic outlook in the near term, with a relatively solid earnings per share growth rate of 198.05% over the next 1-2 years. The business's quarterly revenue was up 13.3% on a year-over-year basis. equities analysts forecast that Chemours will post 3.65 earnings per share for the current year. This buyback authorization permits the specialty chemicals company to repurchase shares of its stock through open market purchases. Stock buyback plans are often an indication that the company's leadership believes its stock is undervalued. Investors of record on Thursday, February 15th will be issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 1.43%. Its down 0.79% from 1.02M shares previously. The ex-dividend date of this dividend is Wednesday, February 14th. The Chemours Company (CC) has an operating margin of 8.50%. The shares were sold at an average price of $53.68, for a total transaction of $1,019,920.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

In other Chemours news, insider E Bryan Snell sold 11,878 shares of the business's stock in a transaction on Monday, November 6th.

This particular stock's 5-day moving average is 51.51, its 20-day moving average is 51.64 and its 100-day moving average is 50.68. Following the completion of the sale, the senior vice president now directly owns 47,356 shares of the company's stock, valued at approximately $2,652,409.56. The disclosure for this purchase can be found here. Corporate insiders own 1.14% of the company's stock. Jefferies maintained The Chemours Company (NYSE:CC) rating on Friday, June 16. TIAA CREF Investment Management LLC boosted its holdings in Chemours by 126.5% during the second quarter. Koch Industries Inc. acquired a new position in Chemours in the second quarter valued at $704,000. TIAA CREF Investment Management LLC now owns 1,789,112 shares of the specialty chemicals company's stock valued at $67,843,000 after acquiring an additional 999,380 shares in the last quarter. Great West Life Assurance Co. Can grew its stake in Chemours by 1.2% in the second quarter. Can now owns 110,566 shares of the specialty chemicals company's stock worth $4,191,000 after purchasing an additional 1,355 shares in the last quarter. World Asset Management Inc grew its stake in Chemours by 4.0% in the second quarter. FMR LLC now owns 15,830,411 shares of the specialty chemicals company's stock worth $600,289,000 after purchasing an additional 905,038 shares during the last quarter. Finally, Korea Investment CORP grew its stake in Chemours by 99.8% in the second quarter. The brokerage presently has a "buy" rating on the specialty chemicals company's stock. Institutional investors and hedge funds own 74.42% of the company's stock. CC has been the topic of a number of research analyst reports. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of USA and global copyright laws. The legal version of this piece of content can be read at https://weekherald.com/2017/12/06/chemours-cc-pt-raised-to-66-00.html.

The Chemours Company is a provider of performance chemicals. It operates through three divisions: Titanium Technologies, Fluoroproducts, and Chemical Solutions.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE